USPTO serial 77880998
INVITROGEN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 22, 2011
- Examiner
- WEIGLE, KATHERINE CONNOLLY
- Law office
- TMEG LAW OFFICE 101
What this means
Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection. Calendar the next Section 8 and 9 deadline in 10 years and maintain monitoring.
Need help with INVITROGEN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kenya L. Williams
Kenya L. Williams Thermo Fisher Scientific5781 Van Allen WayCarlsbad, CA 92008United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | [ Reagents and kits comprised of reagents for scientific or medical research use; diagnostic reagents and kits comprised of diagnostic reagents for scientific or medical research use; diagnostic reagents for clinical or medical laboratory use; cellular pathway exploration tools, namely, enzyme-linked immunosorbent assay (ELISA), kinase activity assays, protein arrays, recombinant proteins and antibodies for analysis of multiple proteins and pathways for research purposes; key human, mouse and rat markers and antibodies conjugated to other proteins, namely, cytokines and chemokines for use in flow cytometry; cell and tissue culture media for non-medical use, cell/tissue culture growth supplements in the nature of biochemicals, reagents for use in cell/tissue cultures, and cells, all for use in scientific, laboratory, and medical research; In vitro ADME cell products, namely, fresh and cryopreserved hepatocytes and liver subcellular fractions, and transporters derived from a variety of species, including human, non-human primate, dog, rat and mouse, all for scientific, laboratory or medical research; Magnetic particle-based biomedical separation systems comprising magnetizable polymer beads, the attached antibody and the magnetic particle concentrator for separating a specific selected cell population from a larger, more complex cell population. Biological and biochemical preparations, namely, reagents and kits consisting of proteins, PCR fragments, cDNA libraries, vectors, enzymes, molecules, clones, genes, cell, recombination proteins and sites, restriction enzymes, primers, plasmids, and reagents all for scientific medical research, or research use; Microbiological culture media, animal blood sera, mammalian and insect cells, mammalian and insect cell culture media and cell culture reagents, all for medical laboratory use; full line of kits consisting primarily of one or more of the following, namely, protein arrays, nucleic acids, hormones, purification supports, resins, cells, gels, probes, buffers, stains and associated reagents and devices for the expression, amplification, purification and analysis of biological samples for scientific or medical research use; fluorescent chemicals for use in scientific research; electrophoresis gel and chromatography chemicals, buffers, and solutions for scientific research; research and diagnostic biochemical and biological reagents, other than for medical or veterinary purposes, for agricultural, ecological, DNA typing, food processing and research use; reagents and assays used for detection and quantitation of DNA, RNA, protein or other analytes in solution, sold individually or in kits for research use; chemical reagents for non-medical purposes for the detection of pathogens and/or toxins in environmental samples; synthetic DNA for use in biotechnology; synthetic DNA and molecules used as DNA molecular weight standards in biotechnology fields; nucleotide arrays for scientific research; biochemical reagents for scientific research; buffers for use in analytical chemistry all for scientific and medical research use; chemicals, namely, reagents containing ligands, effector molecules and antibodies for scientific or medical research use; antibody-conjugated micro-beads and antibody-conjugated microspheres all for scientific and medical research use and for activation of immune system cells; fluorescent chemical dyes for clinical or medical laboratory use, namely, for measurement of pH in medical laboratories ] | SECTION 8 - CANCELLED | Sep 4, 2004 |
| 005 | [ Microbiological culture media, animal blood sera, mammalian and insect cells, mammalian and insect cell culture media and cell culture reagents, all for medical diagnostic use; diagnostic biochemical and biological reagents for use in detection or treatment for medical purposes; chemical reagents for the detection of pathogens and/or toxins in veterinary samples; pharmaceuticals preparations and compositions for therapeutic use, namely, for expanding, selecting and deleting cells of the immune systems; preparations and compositions for therapeutic use, namely, for activating cells of the immune systems; pharmaceutical preparations for use in the treatment of cancer, infectious diseases and immunodeficiencies; antibody-conjugated beads, antibody-conjugated micro-beads and antibody-conjugated microspheres for promoting a therapeutic effect on the body; chemical reagents for medical purposes ] | SECTION 8 - CANCELLED | Sep 4, 2004 |
| 009 | [ Computer software used for the collection, organization, analysis, integration and communication of scientific data; computer software used to operate laboratory instruments; laboratory instruments, namely, nucleic acid sequencers and synthesizers, genetic analyzers, thermal cyclers, cytometers, protein and peptide synthesizers, mass spectrometers and chromatographs, ] laboratory instruments for preparation of nucleic acid samples [, laboratory robots ]; laboratory supplies, namely, [ racks, vials, caps, septa, needles, bottles, flasks, filters, tubes, and seals, plastic tray covers, micro plates, ] pipette tips [, reagent reservoirs, optical heat field covers, plastic cards, and plastic capillary arrays; all for scientific and research use and diagnostics use; computer software for the construction of recombinant DNA molecules in the fields of molecular biology and genetics, building of functional or restriction maps, describing recombinant molecules, and obtaining the exact nucleotide sequences of recombinant DNA molecules; and computer software for use in database management in the fields of molecular biology and genetics that may be downloaded from a global computer network and computer software for use in database management in the fields of molecular biology and genetics; laboratory instruments, namely, magnetic particle concentrator to be used with magnetic particle-based biomedical separations; apparatus for protein and nucleic acid electrophoresis. Optical filters for wavelengths of light; detectors and/or analyzers, and components thereof, of proteins, nucleic acids, cellular metabolites, carbohydrates, viruses, bacteria and eukaryotic cells not for medical diagnostic use; laboratory instrument for performing automated washing, dispensing, hybridization, and imaging of chip based sequence specific oligonucleotides; fluorometer or spectrophotometer used for detection and quantitation of DNA, RNA, protein or other analytes in solution with detachable power cord; detachable Universal Serial Bus (USB) data cord; scientific apparatus, namely, assay tubes; software for analysis or results, all for use with a fluorometer or spectrophotometer; laboratory instrument for the detection of pathogens and/or toxins in a sample; laboratory equipment, namely, apparatus in the nature of biochips for identification, detection of presence of biological or chemicals in a sample and determination of physical or chemical properties of a sample; synthesizers for making polymer arrays and replacement parts therefor, and hybridization stations for making fluidic and microfluidic devices ] | ACTIVE | Sep 4, 2004 |
| 042 | [ Providing an on-line computer database featuring information in the field of scientific and medical research; consultation and research in the fields of science, technology, medicine and health, namely, nucleic acid sequencing, analysis and synthesis of oligonucleotides and other molecules for others for use in life science research and biotechnology research; computer services, namely, providing temporary use of on-line non-downloadable software for accessing and analyzing information in the field of science, technology, medicine, health and public policy; medical, research and laboratory diagnostic services in the field of nucleic acid sequencing, analysis and synthesis of oligonucleotides and other molecules for others for use in life science research and biotechnology research; product development for others; laboratory services, namely, nucleic acid sequencing, synthesis and analysis, analysis and synthesis of oligonucleotides and other molecules for others for use in life science research and biotechnology research; installation, maintenance and repair of computer software for scientific, research, medical, and diagnostic use; nucleic acid analysis; genetic research, namely, gene discovery; genetic disease research, genomics and gene expression research and development; pharmacokinetic research services; proteomics research services; gene identification, gene cloning, gene expression, gene mapping, electrophoresis, protein purification and analysis, and protein interaction detection, all for scientific and medical research purposes; medical and scientific research; medical and scientific research for the development and commercialization of cell-based therapeutic immune system stimulators and enhancers to treat cancer and infectious diseases; technical research and consultation services related thereto in the fields of pharmaceuticals, medicine, biological sciences, immunotherapy, and medical devices; technical consultation services in the fields of development of pharmaceutical preparations and medicines, biological sciences, immunotherapy, and troubleshooting in the nature of diagnosing problems with medical devices; development of new products in the fields of pharmaceuticals, medicine, biological sciences, immunotherapy, and medical devices for others; medical laboratory services; research and development for new immunotherapy products for others; biopharmaceutical research and development; scientific research services; medical laboratory testing and diagnostic services for others in the fields of science and research related thereto; scientific research, namely, developing customized microbiological, mammalian, and insect culture media, media formulations, and cell culture reagents, and evaluating culture media for others; contract laboratory services, namely, drug-drug interaction studies, drug metabolism studies and hepatotoxicity studies, focused primarily on enzyme induction and inhibition, reaction phenotyping, metabolite stability and profiling, and P-gp assays and consulting services related thereto ] | SECTION 8 - CANCELLED | Sep 4, 2004 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Life Technologies Corporation
- Other trademarks owned by Life Technologies Corporation
- Other trademarks owned by Life Technologies Corporation
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Similar marks named INVITROGEN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 12, 2025 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Aug 12, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 12, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 12, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 12, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 12, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 27, 2022 | NAS8 | NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED | — |
| May 27, 2022 | RNL1 | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| May 27, 2022 | 9G8P | REGISTERED - SEC. 9 GRANTED/CHECK RECORD FOR SEC. 8 | — |
| May 27, 2022 | 8PRT | REGISTERED - PARTIAL SEC. 8 (10-YR) ACCEPTED | — |
| May 19, 2022 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Nov 22, 2020 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Dec 20, 2017 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Dec 20, 2017 | C15P | REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Dec 15, 2017 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Nov 21, 2017 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Nov 22, 2016 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jul 23, 2014 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 23, 2014 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 22, 2011 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 19, 2011 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Oct 18, 2011 | REGV | LAW OFFICE REGISTRATION REVIEW COMPLETED | — |
| Oct 18, 2011 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Oct 18, 2011 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 17, 2011 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Oct 17, 2011 | IUAF | USE AMENDMENT FILED | — |
| Oct 17, 2011 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Oct 14, 2011 | EXT2 | SOU EXTENSION 2 FILED | — |
| Oct 14, 2011 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Oct 14, 2011 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 2, 2011 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 2, 2011 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 30, 2011 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 29, 2011 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jun 29, 2011 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jun 27, 2011 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jun 27, 2011 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 1, 2011 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 28, 2010 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Nov 2, 2010 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 2, 2010 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 25, 2010 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Sep 25, 2010 | ALIE | ASSIGNED TO LIE | — |
| Sep 17, 2010 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 16, 2010 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 16, 2010 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 16, 2010 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 4, 2010 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 4, 2010 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 4, 2010 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 22, 2010 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 21, 2010 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 21, 2010 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 21, 2010 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 21, 2010 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 21, 2010 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 19, 2010 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 2, 2009 | MDSM | NOTICE OF DESIGN SEARCH CODE MAILED | — |
| Dec 1, 2009 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 28, 2009 | NWAP | NEW APPLICATION ENTERED | — |